New drug for MS is milestone for patients and research

A new drug, Ocrevus (ocrelizumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat multiple sclerosis (MS). The National Multiple Sclerosis Society says it’s a “game changer” and Mayo Clinic neurologist Dr. Dean Wingerchuk says, “The approval of ocrelizumab is an important milestone both for people with MS and MS research.”

In a news statement released Wed. March 29, Dr. Billy Dunn, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research says, “This therapy not only provides another treatment option for those with relapsing MS, but for the first time provides an approved therapy for those with primary progressive MS.”

More health and medical news on the Mayo Clinic News Network http://newsnetwork.mayoclinic.org/

source